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Abstract
Background:Cyclooxygenase-2 (COX-2) is a key enzym e involved in the conversion of arachidonic acid into prostaglandins. 
COX-2 is mainly induced at sites of inflammation in response to  proinflammatory cytokines such as interleukin-1 a/ß, 
interferon-c and tum or necrosis factor-a produced by inflammatory cells.
Aim:The aim of this study was to  investigate the possible m odulating effect of the functional COX-2 polym orphisms — 7795 
Ar G and —765Gr C on th e  risk for developm ent of inflammatory bowel disease (IBD) in a Dutch population.
Methods:Genomic DNA of 525 patients with Crohn's disease (CD), 211 patients with ulcerative colitis (UC) and 973 healthy 
controls was genotyped for the — 7 795 Ar G (rs689466) and —765Gr C (rs20417) polymorphisms. Distribution of genotypes 
in patients and controls w ere com pared and genotype-phenotype interactions were investigated.
Results:The genotype distribution of the — 7 795Ar G polymorphism was not different betw een the patients with CD or UC 
and the control group. The —765GG genotype was more prevalent in CD patients com pared to  controls with an OR of 1.33 
(95%CI 1.04-1.69, p<0.05). The —765GC and —765CC genotype carriers show ed a tendency to  be less frequent in patients 
with CD com pared to  controls, with ORs of 0.78 (95%CI: 0.61-1.00) and 0.49 (95%CI 0.22-1.08), respectively. Combining 
homozygous and heterozygous patients with the —765C allele show ed a reduced risk for developing CD, with an OR of 0.75 
(95%CI: 0.59-0.96). In the  context of this, the  G—1195G—765/A —1195C—765 diplotype was significantly less com m on in patients 
with CD com pared to  controls, with an OR of 0.62 (95%CI: 0.39-0.98). For UC however, such an effect was not observed. No 
correlation was found betw een COX-2 diplotypes and clinical characteristics of IBD.
Conclusions: The —765Gr C polymorphism was associated with a reduced risk for developing Crohn's disease in a Dutch 
population.
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Introduction
Inflammatory bowel disease (IBD) is an idiopathic, chronic, 
relapsing auto inflammatory disorder of the gastro-intestinal tract. 
The two major types of IBD are C rohn’s disease (CD) and 
ulcerative colitis (UC). Genetic, immunological and environmental 
factors are thought to play a role in the pathogenesis of IBD [1]. A 
dysregulated immune response against the intestinal microbiota in 
genetic susceptible individuals has been heavily implicated in the 
pathogenesis of inflammatory bowel disease [2]. Therefore, genes 
involved in inflammatory responses are under investigation to look 
for variants predisposing to IBD.
Cyclooxygenase (COX) is a modifier gene and key enzyme in 
the conversion of free arachidonic acid into prostaglandins and is 
involved in the regulation of inflammatory processes through its
products, mainly prostaglandin E2 (PGE2) [3]. The C O X  family 
consists of two main isozymes: COX-1 and COX-2. COX-1 is 
constitutively expressed in most cell types, including the mucosal 
compartment of the gastrointestinal tract, and is im portant for 
maintaining mucosal integrity, mucosal defence and regulation of 
the mucosal blood flow [4,5]. Being very low expressed in the 
normal gut mucosa, COX-2 expression can be induced by 
mitogenic and proinflammatory stimuli [5,6].
The relevance of COX-2 in the pathogenesis of IBD has been 
demonstrated; increased expression of COX-2 has been observed 
in colonic epithelial cells, the myenteric plexus and in the medial 
layer of arteries from patients with active IBD [7-9]. In addition, a 
relationship between endoscopic activity of IBD and mucosal 
COX-2 mRNA levels was noticed [10]. Although COX-2 is 
involved in the regulation of inflammatory processes, it also seems
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Table 1. Clinical characteristics of patients with Crohn's
disease (n = 525).
Characteristics (% )
Age at diagnosis 27.1 610.7
Family history of IBD* 75/272 (27.6)
Disease localization
Ileal 187 (35.6)
Colonic 127 (24.2)
Ileocolonic 211 (40.2)
Isolated upper disease+ 36 (6.9)
Disease behaviour CD
Non stricturing, non penetrating 176 (33.5)
Stricturing 89 (17.0)
Penetrating 260 (49.5)
Extra-intestinal disease* 161/491 (32.8)
Peri-anal disease* 180/509 (35.4)
Surgery 320 (61.0)
+Patients could be classified as having disease localisation in the upper 
gastrointestinal tract next to ileal, colonic or ileocolonic localisation.
*Note that data of patients are missing. 
doi:10.1371/journal.pone.0015011.t001
to play a physiological role in the defence of the gastric mucosa, as 
well as in the maintenance of gastric mucosal integrity when other 
defence mechanisms are impaired or COX-1 activity is latent 
[3,5]. Moreover, COX-2 seems to be a major contributor to the 
processes that lead to resolution of inflammation [11]. In line with 
this, the use of non-steroidal anti-inflammatory drugs (NSAIDs) in 
patients with IBD, may be associated with exacerbation of the 
underlying IBD and gastrointestinal-related complications [12­
14]. Overall, these findings suggest that COX-2 has a dual role by 
both initiation as well as resolution of inflammation.
Functional polymorphisms in the COX-2 promoter, being
— 765Gr C (rs20417) and — 1195Ar G (rs689466), may alter the 
enzyme function of COX-2 by differential regulation of COX-2 
expression [15]. Recently, a study by 0stergaard  et al. reported an 
association of the — 765Gr C polymorphism with IBD in a Danish 
population [16]. Another study from a previous relatively small 
sample size study performed in the Netherlands however, showed 
no association between these two polymorphisms and IBD [17]. 
We therefore investigated the COX-2 —1195 Ar G and
— 765Gr C polymorphisms in relation to the development and 
clinical severity of IBD in a phenotypically well characterized and 
relatively large IBD cohort of Dutch origin and hypothesized that 
carriers of the —1195 A r G an d /o r —765Gr C polymorphisms 
might be at risk for developing IBD.
Materials and Methods
Patients and controls
This case-control study included 736 patients with inflamma­
tory bowel disease (39% men, mean age 45.0613.9 years), being 
525 patients with C rohn’s disease (35% men, mean age 
44.5613.9) and 211 patients with ulcerative colitis (48% men, 
mean age 46.1614.0) and 973 disease-free controls (43% men, 
mean age 47.2616.6 years). All patients were of Dutch origin and 
were recruited from the outpatient clinic of the Radboud 
University Nijmegen Medical Center, the Netherlands. Controls 
were recruited from the Nijmegen area by advertisement in local
Table 2. Clinical characteristics of patients with Ulcerative
Colitis (n = 211).
Characteristics (% )
Age at diagnosis 32.9612.7
Disease localization*
Proctitis 13/203 (6.4)
Left sided 70/203 (34.5)
Extended/pancolitis 120/203 (59.1)
Surgery 59 (28.0)
*Note that data of 8 patients are missing.
doi:10.1371/journal.pone.0015011.t002
papers. The clinical characteristics of the patients are summarized 
in Tables 1 and 2. Diagnosis of inflammatory bowel disease was 
based on accepted clinical, endoscopic, radiological and histolog­
ical findings [18]. Clinical data of the patients were retrieved by 
retrospective collection from patients’ clinical charts. Phenotypes 
of the patients were described according to age of onset, necessity 
of surgery, family history of IBD, the occurrence of extra-intestinal 
manifestations and maximum extent of disease according to the 
Vienna [19] and Montreal [20] classifications for C rohn’s disease 
and ulcerative colitis respectively.
Information on development of dysplasia and colorectal cancer 
(CRC) in our patient cohort was retrieved using PALGA, the 
nationwide network and registry of histopathology and cytopa- 
thology in the Netherlands [21].
The ethical committee of region Nijmegen and Arnhem reviewed 
and approved the protocol under number CW OM -nr 9804-0100. 
Verbal informed consent was obtained from each patient before 
study participation in agreement with the approval and all samples 
were anonymized. Since research data were collected anonymously, 
at least verbal informed consent was needed according to national 
regulations. Therefore, no written informed consent procedure was 
introduced at time of data collection.
Genotyping
Whole blood from patients and healthy controls was obtained 
by venapuncture in sterile vacutainer tubes, anti-coagulated with 
EDTA and stored at —20°C until use. DNA from patients and 
controls was isolated from whole blood using the Pure Gene DNA 
isolation kit, according to the instructions of the manufacturer 
(Gentra Systems, Minneapolis, MN) and stored at 4°C. Genotypes 
of the COX-2 —1195Ar G polymorphism was determined by 
polymerase chain reaction (PCR)-based restriction fragment 
length polymorphism assays, as described by Zhang et al [15]. 
The COX-2 — 765Gr C polymorphism was determined by a dual­
color discrimination assay using the iCycler iQ  Multicolour Real­
Time Detection System (Bio-Rad Laboratories, Hercules, CA), as 
described by Peters et al [22].
Statistical analysis
Baseline and clinical characteristics were analysed with standard 
descriptive statistics. The observed genotype frequencies were tested 
for deviation from the Hardy-Weinberg equilibrium. Estimates of 
linkage disequilibrium (LD) between SNPs were determined by 
calculating pair-wise D ' and r2 statistics in unrelated individuals, 
using Haploview. Differences in —1195Ar G and —765Gr C 
genotype distributions between the patient and control groups were 
determined by Chi-square analysis. Odds ratios (ORs) with 95%
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Table 3. Distribution of the COX-2 —7 795 and —765 genotypes and corresponding ORs in patients with IBD, CD or UC versus 
controls.
Genotype All patients with IBD Patients with Crohn's Patients with Ulcerative
COX-2 (n = 736) disease (n = 525) Colitis (n = 211)+ Controls
Number
(% ) OR (95%  CI) p-value
Number
(% ) OR (95%  CI) p-value
Number
(% ) OR (95%  CI) p-value n = 973 (% )
— 7 795AA 476 (64.7) Reference - 339 (64.6) Reference - 137 (64.9) Reference - 618 (63.5)
— 7 795GA 221 (30.0) 0.91 (0.74-1.12) 0.38 159 (30.3) 0.92 (0.73-1.16) 0.48 62 (29.4) 0.89 (0.64-1.23) 0.48 315 (32.4)
— 7 795GG 39 (5.3) 1.27 (0.80-2.00) 0.31 27 (5.1) 1.23 (0.74-2.04) 0.42 12 (5.7) 1.35 (0.69-2.65) 0.38 40 (4.1)
—765GG  535 (73.2) Reference - 394 (75.0) Reference - 141 (68.4) Reference - 675 (69.4)
—765GC  179 (24.5) 0.84 (0.67-1.04) 0.11 123 (23.4) 0.78 (0.61-1.00) 0.05 56 (27.2) 0.99 (0.71-1.40) 0.97 270 (27.7)
—765CC  17 (2.3) 0.77 (0.42-1.41) 0.39 8 (1.5) 0.49 (0.22-1.08) 0.07 9 (4.4) 1.53 (0.71-3.33) 0.27 28 (2.9)
+In the ulcerative colitis group, there are some missing data (n = 5) due to unsuccessful PCR for the —76 5  Gr C polymorphism.
OR=Odds ratio; CI =confidence interval.
doi:10.1371/journal.pone.0015011.t003
confidence interval (95% CI) were calculated for genotypes 
associated with predicted normal versus predicted altered enzyme 
activities (variant genotypes) between IBD patients and controls. 
These analyses were also applied for testing of either UC or CD with 
the control group. Based on the two polymorphisms investigated, a 
diplotype analysis was performed. Diplotypes were compared with 
regard to phenotypical characteristics and comparisons were given 
as ORs with 95% CI. Additionally, we investigated in patients with 
IBD whether the —1195Ar  G and — 765Gr  C polymorphisms were 
associated with development of mucosal dysplasia or colon cancer. 
Data analysis was performed using SPSS software (Version 16.0, 
SPSS, Chicago, IL, USA). A p-value of <0.05 was used as a 
criterion for statistical significance.
Results
In this study 736 patients with inflammatory bowel disease, 525 
patients with C rohn’s disease and 211 patients with ulcerative 
colitis as well as 973 healthy controls were included. No statistical 
significant differences were observed between patients with IBD 
and controls regarding age and gender. However when the CD or 
UC patient groups were compared to controls separately, 
significant more females were present in the group with Crohn’s 
disease (p<0.01).
Distribution of the —1195 and — 765 COX-2 genotypes in both 
patient and control groups fitted the H ardy Weinberg equilibrium; 
for the —1195 genotypes, p-values of p = 0.14, p = 0.17 and 
p = 0.99, for the patients with C rohn’s disease, ulcerative colitis 
and controls were found; whereas corresponding p-values for the
— 765 genotypes were p = 0.64, p = 0.26 and p = 0.87, respectively. 
As been reported before by others [15,17,23], both SNPs were 
found to be in strong linkage disequilibrium (D' = 1, r2 = 0.05).
Genotype distribution and association with inflammatory 
bowel disease
The distribution of the —1195 and —765 COX-2 genotypes as 
found in patients with IBD and controls is given in Table 3. The
— 1195 genotype distribution was not different between the 
patients with C rohn’s disease, ulcerative colitis, or all IBD patients 
taken together in comparison with the control group. However, 
the —765 genotype distribution showed a tendency towards a 
significant difference between patients with C rohn’s disease and 
controls, with the —765GC and —765CC genotypes being less 
prevalent in patients, with ORs of 0.78 (95%CI 0.61-1.00,
p<0.05) and 0.49 (95%CI 0.22-1.08) respectively and the
— 765GG genotype being more prevalent in patients (OR 1.33, 
95%CI 1.04-1.69, p<0.05). No differences were found between 
patients with ulcerative colitis and controls. Combining homozy­
gous (—765CC) and heterozygous (_765GC) patients bearing the
— 765C allele, showed a reduced risk for developing Crohn’s 
disease in this group (OR = 0.75, 95%CI 0.59-0.96, p<0.05).
The effects of the two COX-2 polymorphisms were then studied 
in the context of diplotypes. Six diplotypes were identified, with 
the A _ 1195G _ 765 /A _ 1195G _ 7 6 5  diplotype being the most preva­
lent in both patients and controls (Table 4). The G —1 195G _765/  
A _ 1195C _ 765 diplotype was significantly less frequent in patients 
with C rohn’s disease compared to controls with an O R  of 0.62 
(95%CI: 0.39-0.98, p<0.05).
Correlation of the COX-2 diplotypes with clinical 
characteristics of IBD patients
Additionally, clinical characteristics of patients with Crohn’s 
disease and ulcerative colitis were studied in the context of 
diplotypes in which the most common A _ 1195G _ 765 /A _ 1195G _ 7 6 5  
diplotype served as reference. No significant association between 
the COX-2 diplotypes and clinical characteristics of either Crohn’s 
disease or ulcerative colitis was found (Tables 5 and 6). W hen data 
were corrected for age and gender, no significant changes in data 
were observed.
COX-2 polymorphisms and the risk for developing 
dysplasia and colon cancer in patients with inflammatory 
bowel disease
The PALGA search regarding dysplasia and colon cancer in our 
IBD cohort demonstrated that 29 patients (15 patients with CD 
and 14 patients with UC) developed mucosal dysplasia, which is 
regarded as a pre-malignant phase of CRC. Furthermore, in the 
CD cohort 7 patients with CRC were identified; 4 having the 
A _ 1195G _ 765 /A _ 1195G _ 7 6 5  diplotype and 3 having the 
G _ 1195G _ 765 /A _ 1195G _ 7 6 5  diplotype. In the UC cohort, no 
patients were identified who developed CRC. W hen tested, no 
association was found between the COX-2 diplotypes and the 
development of colonic dysplasia or cancer (Tables 5 and 6).
Discussion
This study was performed to determine the possible modulating 
effect of the COX-2 —1195 Ar G and — 765Gr C polymorphisms
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Table 4. COX-2 diplotype distribution and corresponding ORs in patients with IBD, CD or UC versus controls.
Patients with IBD
Diplotype
COX-2 All patients Crohn's disease Ulcerative colitis Controls
n = 731 n = 525 n = 206
(% ) OR (95%  CI) p-value (% ) OR (95%CI) p-value (% ) OR (95%CI) p-value n = 973 (% )
A — 
A  _
7 95G — 76sf 
7 95G — 765
322 (43.8) Reference - 237 (45.1) Reference - 85 (4Q.3) Reference - 395 (4Q.6)
G _ 
A  _
7 95G —7655 
7 95G — 765
174 (23.6) Q.9Q (Q.7Q-1.15) Q.38 13Q (24.8) Q.91 (Q.7Q-1.19) Q.49 44 (2Q.9) Q.86 (Q.58-1.28) Q.45 238 (24.5)
A  _ 
A  _
7 95G — 76s5  
7 955e — 765
133 (18.1) Q.84 (Q.65-1.1Q) Q.2Q 94 (17.9) Q.81 (Q.6Q-1.Q8) Q.15 39 (18.5) Q.93 (Q.62-1.42) Q.75 194 (19.9)
G 
A  _
7 95G —765/ 
7 955e — 765
46 (6.5) Q.72 (Q.49-1.Q7) Q.11 29 (5.5) Q.62 (Q.39-Q.98) Q.Q4 17(8.1) 1.Q1 (Q.57-1.8Q) Q.97 78 (8.Q)
G
G
7 95G —765/ 
7 95G —765
39 (5.3) 1.2Q (Q.75-1.9Q) Q.45 27 (5.1) 1.13 (Q.67-1.88) Q.65 12 (5.7) 1.39 (Q.7Q-2.77) Q.34 4Q (4.1)
A  _ 
A  _
7 955e  — 7655 
7 955e — 765
17 (2.3) Q.75 (Q.4Q-1.39) Q.35 8(1.5) Q.48 (Q.21-1.Q6) Q.Q6 9 (4.3) 1.49 (Q.68-3.28) Q.32 28 (2.9)
OR = Odds ratio; CI = confidence interval. 
doi:1Q.1371/journal.pone.QQ15Q11.tQQ4
on the risk of developing inflammatory bowel disease. Carriers of 
the — 765C allele showed a reduced risk for developing CD. This 
result suggests that the — 765Gr C change induces an altered 
enzyme expression and enzyme activity with potential anti­
inflammatory consequences.
Studies regarding the functional consequences of the
— 765Gr C polymorphism in the COX-2 prom oter are conflicting. 
Therefore, the (physiological) consequences of our findings are 
difficult to interpret. First of all, the — 765C-containing COX-2 
promoter was reported to drive lower reporter gene expression in 
vitro compared to the — 765G-containing counterpart [15,24]. 
Furthermore, serum prostaglandin E 2 (PGE2) concentrations of 
renal transplant recipients patients with the GG genotype were 
significantly higher than PGE2 concentrations from patients with 
the C allele [25]. Subsequent work from Zhang and coworkers 
showed that the — 7 6 5 G rC  polymorphism creates a binding site 
for nucleophosmin (NPM) and phosphorylated nucleophosmin (p- 
NPM), which acts as an inhibitor of COX-2 transcription [26]. 
The —1195 A r G  polymorphism creates a c-MYB binding site, 
which can activate COX-2 expression, and displays a higher 
promoter activity [15].
In normal colorectal mucosa COX-2 expression is enhanced in 
patients with IBD when compared to subjects with normal 
colonoscopy [27]. Taken together in light of our results, this would 
imply that low levels of COX-2 are associated with an reduced risk 
for developing CD. In vitro however, when cells were treated with 
smoking condensate, the 765C-containing promoter exerted a 
significantly higher reporter gene expression compared to the
— 765G-containing counterpart [26]. Besides this, Szczeklik and 
co-workers reported an increased production of prostaglandin E2  
and D 2 (PGE2 and PG D 2) by monocytes obtained from female 
patients with asthma who were homozygous for the — 765C 
variant of the COX-2 gene [28,29]. In the context of IBD, PG E2 
appears to play a dual role. In IBD, PGE2 production is increased 
[30] and in an experimental model of IBD high levels of PG E2 
exacerbate inflammation [31]. O n the other hand, PG E2 signaling 
is required for suppressing colitis symptoms and protecting 
mucosal damage by maintaining the integrity of the epithelial 
intestinal wall, presumably through the enhancement of epithelial 
survival and regeneration [32]. Furthermore, PG E2 has been
recently identified to promote naive T  cell differentiation to IL-17 
-p roduc ing  T  helper (Th17) cells, a subset of T  helper cells which 
have been implicated as potent effector cells in IBD [33].
Several limitations of our study should be noticed. First of all we 
were not able to retrieve the smoking status of our patients and 
controls, as Zhao et al. [26] demonstrated an effect of smoking on 
the expression of the — 765Gr C polymorphism. Secondly, the 
effect of the COX-2 —1195 Ar G and — 765Gr C polymorphisms 
on colonic mucosal COX-2 expression an d /o r PG E2 production 
in patients with IBD is unknown. However regardless of these 
data, the functional consequences of PG E2 in IBD still remains 
conflicting as pointed out above.
The results of our study are in conflict with a Danish case 
control study by 0stergaard  et al. who identified that carriers of 
the homozygous — 765CC variant had a relatively high risk for 
developing CD as well as UC, with an O R  of 2.78 (95%CI = 1.33­
5.88, p = 0.006) and 2.63 (95%CI = 1.35-5.26, p = 0.005) respec­
tively [16]. The — 765CC variant however is very rare in our 
population of IBD patients (n= 17 , 2.3%) and controls (n = 28, 
2.9%) as is the case in another Dutch study by Cox et al. in which 
(2.4%) of the patients and (2.4%) of the controls had this variant 
[17]. In the study of Cox et al., no significant association between 
the — 1195 Ar G and — 765Gr C polymorphisms and IBD was 
found, although the number of patients with IBD involved 
(n = 291) was rather small. However, a recent subsequent study 
from the Danish group of 0stergaard  and co-workers extended 
the original data with data from Scottish IBD patients and showed 
no association any more with the — 765Gr C polymorphism and 
development of IBD [34]. The differences between our results and 
the Danish and Scottish findings could be attributed to the fact 
that the genetical contribution to the etiology of IBD in the 
northern part of Europe differs from central Europe. Mutations in 
the three common CD-associated variants of CARD15, R702W, 
G908R and 1007fsinsC, are relatively rare in Northern countries 
including Denmark and Scotland, while the mutation frequencies 
are relatively high in Central Europe [35].
As stated before, patients with IBD show increased expression of 
COX-2 in the gastrointestinal tract [7,8,10,27]. This increased 
expression of COX-2 has also been observed in gastrointestinal 
adenocarcinomas and in UC-associated neoplasia [36,37]. Addi-
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Table 5. Diplotype-phenotype correlations in patients with Crohn's disease.
A G / 
A G *
G G /
A G Odds ratio
A G /
p-value A C  Odds ratio
G G /
p-value A C  Odds ratio
G G /
p-value G G Odds ratio
A C /
p-value A C Odds ratio p-value
(95%CI) (95%C I) (95%CI) (95%CI) (95%CI)
Disease localization (n = 525)
Ileal 83 51 Reference - 34 Reference - 8 Reference - 8 Reference - 3 Reference -
Colonic 63 26 0.67 (0.38-1.19) 0.17 23 0.89 (0.48-1.66) 0.72 8 1.32 (0.47-3.70) 0.60 6 0.99 (0.33-2.99) 0.98 1 0.44 (0.05-4.32) 0.47
Ileocolonic 91 53 0.95 (0.58-1.54) 0.83 37 0.99 (0.57-1.73) 0.98 13 1.48 (0.59-3.76) 0.41 13 1.48 (0.59-3.76) 0.41 4 1.22 (0.26-5.60) 0.80
Isolated upper disease+ 18 7 0.63 (0.25-1.62) 0.34 8 1.09 (0.43-2.73) 0.86 2 1.15 (0.23-5.89) 0.86 1 0.58 (0.07^4.90) 0.61 0 - 0.42
Disease behavior (n = 525)
Non stricturing/ 75 44 Reference - 37 Reference - 10 Reference - 8 Reference - 2 Reference -
penetrating
Stricturing 43 18 0.71 (0.37-1.39) 0.32 14 0.66 (0.32-1.36) 0.26 8 1.40 (0.51-3.80) 0.51 4 0.87 (0.25-3.07) 0.83 2 1.74 (0.24-12.83) 0.58
Penetrating 119 68 0.97 (0.61-1.57) 0.91 43 0.73 (0.43-1.24) 0.25 11 0.69 (0.28-1.71) 0.43 15 1.18 (0.48-2.92) 0.72 4 1.26 (0.23-7.05) 0.79
Surgery 146 87 1.26 (0.81-1.98) 0.31 50 0.71 (0.44-1.15) 0.16 16 0.77 (0.35-1.67) 0.50 17 1.06 (0.47-2.42) 0.89 4 0.62 (0.15-2.55) 0.51
Extra-intestinal (n = 491) 77 32 0.69 (0.43-1.13) 0.14 37 1.39 (0.84-2.30) 0.21 8 0.80 (0.34-1.92) 0.62 6 0.64 (0.24-1.67) 0.36 1 0.27 (0.03-2.26) 0.20
Fam ily history of IBD  (n = 272) 36 18 0.82(0.43-1.59) 0.57 14 1.08(0.52-2.26) 0.84 2 0.62(0.13-3.05) 0.55 3 0.67(0.18-2.56) 0.56 2 1.65(0.26-10.28) 0.59
Dysplasia 7 4 1.04 (0.30-3.63) 0.95 1 0.35 (0.04-2.91) 0.31 1 1.17(0.14-9.89) 0.88 2 2.63 (0.52-13.35) 0.23 0 0.62
Colon cancer 4 3 0.73 (0.16-3.30) 0.68 0 - 0.21 0 0.48 0 0.50 0 0.71
Diplotype-phenotype correlations in patients with Crohn's disease in which the AG/AG diplotype served as reference.
+Patients could be classified as having disease localisation in the upper gastrointestinal tract next to ileal, colonic or ileocolonic localisation.
*For full notation see Table 4.
doi:10.1371 /journal.pone.0015011 .t005
Table 6. Diplotype-phenotype correlations in patients with ulcerative colitis.
A G / 
A G #
G G /
A G
Odds ratio 
(95%CI) p-value
A G /
A C
Odds ratio 
(95%CI) p-value
G G /
A C
Odds ratio 
(95%C I) p-value
G G /
G G
Odds ratio 
(95%CI) p-value
A C /
A C
Odds ratio 
(95%CI) p-value
Disease localization 
(n = 198)
Proctitis 6 2 Reference - 2 Reference - 2 Reference - 1 Reference - 0 Reference -
Left sided 27 13 1.44 (0.26-8.16) 0.676 15 1.67 (0.30-9.31) 0.558 7 0.78 (0.13-4.72) 0.784 3 0.67 (0.06-7.57) 0.742 4 ■ 0.351
Pancolitis 46 28 1.83 (0.35-9.68) 0.474 21 1.37 (0.26-7.36) 0.713 8 0.52 (0.09-3.06) 0.465 8 1.04 (0.11-9.86) 0.970 5 - 0.422
Surgery (n = 206) 24 11 0.85 (0.37-1.94) 0.695 11 1.00 (0.43-2.32) 0.997 8 2.26 (0.78-6.54) 0.127 2 0.51 (0.10-2.49) 0.397 2 0.73 (0.14-3.75) 0.701
Dysplasia (n = 211) 5 3 1.17(0.27-5.14) 0.835 2 0.87(0.16-4.67) 0.866 0 - 0.305 1 1.46(0.16-13.63) 0.741 2 4.57(0.75-28.01) 0.076
Diplotype-phenotype correlations in patients with ulcerative colitis in which AG/AG served as reference.
^For full notation see Table 4.
doi:10.1371 /joumal.pone.0015011 .t006
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COX-2 Polymorphisms and Inflammatory Bowel Disease
tionally, the COX-2 —1195 Ar G and —765Gr C polymorphisms 
were demonstrated to influence the expression of COX-2 and 
confer a risk for developing (adeno)carcinomas in the gastrointes­
tinal tract [15,38,39]. Chronic intestinal inflammation-associated 
colorectal carcinogenesis is thought to occur via a stepwise 
progression beginning with epithelial hyperplasia, leading to 
various grades of dysplasia, adenoma, and then to adenocarcino­
ma [40]. We investigated whether or not an association could be 
found between the COX-2 polymorphisms and dysplasia or CRC 
in patients with IBD. Due to the restricted number of patients who 
developed dysplasia or CRC, no differences could be observed.
In conclusion, subjects with the — 765C allele showed a reduced 
risk for developing CD. No correlation could be found between
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the COX-2 diplotypes and clinical characteristics of IBD patients 
and the development of colonic dysplasia or cancer. Further 
studies are required to confirm the association we found and 
efforts should be made to unravel the role of COX-2 and its 
derived prostaglandins in the pathogenesis of IBD.
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